Laborie Medical Technologies Announces Agreement to Acquire Urotronic for up to $600 Million

Recently, Laborie Medical Technologies, Inc. (Laborie), a leading diagnostic and therapeutic medical technology company, signed a definitive agreement to acquire Urotronic, Inc. (Urotronic), a Minnesota-based medical device company pioneering the application of its Optilume® drug-coated balloon technology for use in interventional urology including treating urethral strictures and benign prostatic hyperplasia (BPH).

Since 2015, CD Capital has been a long-term investor and director of Urotronic, participating in its angel round, Series A, B, and C financings through leading and follow-on investments. Prior to this acquisition, CD Capital was also the largest institutional investor in Urotronic.

Under the terms of the agreement, the transaction consists of an upfront cash payment of $255 million, and up to an additional $345 million in potential commercial and reimbursement milestone payments. Net of Laborie's existing minority investment in Urotronic, the net upfront cash payment will be $232 million with net potential milestone payments of up to $314 million.